Xiaochang Shen

No ORCID on file · 2 papers in corpus

review 2025

Clinical relevance of PLK1 in epithelial ovarian cancer

Frontiers in pharmacology ·doi:10.3389/fphar.2025.1702273

Ovarian cancer, particularly epithelial ovarian cancer (EOC), is the most aggressive and lethal gynecologic malignancy, necessitating the development of innovative and potent therapies to improve its prognosis. Human polo-like kinase 1 (PLK…

lab-animal 2025

Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer

Frontiers in pharmacology ·doi:10.3389/fphar.2025.1520771

OBJECTIVE: Chronic inflammation is a key contributor to carcinogenesis, progression, and chemoresistance in ovarian cancer, making inflammatory pathways a logical therapeutic target for the treatment of this disease. Sulindac, a commonly us…